Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov downgraded Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Neutral.

April 29, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acrivon Therapeutics was downgraded from Buy to Neutral by Ladenburg Thalmann analyst Aydin Huseynov.
Analyst downgrades typically lead to a negative short-term impact on the stock price as they may reflect a change in the company's outlook or market position. The downgrade from Buy to Neutral suggests a less optimistic view on ACRV's future price performance, potentially influencing investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100